Distretto Tecnologico Sicilia Micro E Nano Sistemi S.c.a.r.l.

Epitech Group S.r.l.

Epitech Group S.p.a.

Csl Behring Ag

Innovet Italia S.r.l.

Salvatore Cuzzocrea

Francesco Della Valle

Maria Federica Della Valle

Gabriele Marcolongo

Giovanna Pitarresi

Gaetano Giammona

Santa Viola

Anna Rita Blanco

Patrizia Guarneri

Emanuela Esposito

Salvatore Papasergi

Patrizia Saladino

Mariano Licciardi

Emanuela Fabiola Craparo

Grazia Maria Letizia Consoli

Gennara Cavallaro

Irene Ceidda

Guiseppe Granata

Clara La Marca

Maria Luisa Bondi'

Vito Safina

Vincenzo Di Marzo

Christoph Thiemermann

Gillian Cockerill

Chiara Gomiero

Giuseppe Esposito

Maria Luisa Bondi′

Giuliano Claps

Annalisa Noce

Sofia Parrasia

Irene Deidda

Clara La Marco

Giuseppe Granata

Grazia Maria Consoli

Maria Luisa Bondi

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Method for the treatment of COVID-19 infections with palmitoylethanolamide

Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.

Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form

The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.

N-palmitoyl-D-glucosamine in a micronized form

Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.

Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: &#x2014;CH, &#x2014;CHOH, &#x2014;COOCH, &#x2014;COOH. Y may preferably be: &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;CH&#x2014;, CH(CH)&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH(CH)&#x2014;, &#x2014;CH&#x2014;C(CH)&#x2014;, &#x2014;CH&#x2014;CH(CHOH)&#x2014;, &#x2014;CH&#x2014;C((CHOH))&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, &#x2014;CH&#x2014;CH(COOCH)&#x2014;, &#x2014;CH&#x2014;CH(COOH)&#x2014;, for use as a medicine. 

Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases

A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases. The mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or of a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol and said Silymarin, derivatives thereof or conjugates or complexes thereof are formulated for a separate, sequential, concomitant administration or in admixture, also in a co-micronized or co-ultra-micronized form.

Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases

A method for the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, comprises parenteral administration to the patient of an effective amount of high density lipoprotein (HDL).

Treatment of inflammatory conditions of the intestine

Growing community of inventors

Milan, Italy

Salvatore Cuzzocrea